Profile avatar
mariaamaya27.bsky.social
Physician Scientist, University of Colorado | MDS, AML |
17 posts 134 followers 161 following
Regular Contributor

If they fire staff that supports research, physicians and investigators will also be forced to leave…

“There’s going to be a missing age class of researchers that will reverberate for years.” scim.ag/3ERRLDo

CU Cancer Center member Manali Kamdar, MD, started to think about pivoting from her dream of being a dancer to a different profession after receiving care for a spinal injury. Now she is a highly recognized leading lymphoma researcher ⬇️

I believe that most of our society values science and scientists. We need to continue to communicate our findings and value to the public and advocate for increased research funding, especially for young investigators->they are the future.

Excited to share this commentary on a very interesting clinical trial for AML ashpublications.org/blood/articl... @bloodjournal.bsky.social

Fork in the road Q/A: Q: Can I take extended vacation while on administrative leave? A: You are most welcome to stay at home and relax or travel to your dream destination. Sure, let me go take an extended vacation while I leave Veretans hanging without care because we are already short-staffed.

Join us soon for a great session on mechanisms of therapy resistance in myeloid neoplasms. #ASH24

Amazing trainees presenting their amazing work! #ASH24

Fascinating talk by Shanshan Pei on a newly identified TFG-ROS1 fusion, that although rare it can cause CMML -> AML and can be targeted with ALK/ROS1 inhibitors. #AMLsm #ASH24

It’s ASH week! #ASHThrowback to 2019 Orlando plane ride with the amazing lab mate Shanshan Pei who is now a trailblazing independent investigator! He just came to visit and I look forward to his talk on Saturday. #AMLsm

Took me long but better late than never! This is our lab website and this Thanksgiving weekend I am grateful for everyone in the lab, they make science so fun! ladybug-triceratops-dpm6.squarespace.com

4-gene prognostic risk classifier (FLT3-ITD, KRAS, NRAS, and TP53) seems to successfully differentiate outcomes among patients with newly diagnosed AML treated with Aza/Ven than ELN 2017/2022 ashpublications.org/blood/articl...

Hello, #hematology community! ASH is now on BlueSky. We're here to share cutting-edge research and educational resources and connect global experts in blood diseases. Join us in advancing hematology together. Welcome, colleagues! #BloodSky #HemeSky #MedSky

How to make friends with a hematologist Chapter 1 1. Order a peripheral smear before they ask 2. Never get a CBC without a diff 3. Stop the heparin before you call for a HIT consult 4. NEVER order MTHFR 5. Order a reticulocyte count before you consult for anemia

Previous studies have shown self-reported Black patients have inferior treatment and survival outcomes compared to White patients, but why? Our work indicating that underlying genetics influence AML biology is now live at Nature Genetics. www.nature.com/articles/s41...

Thanks to Flatironhealth we were able to analyze AML outcomes across the U.S. based on socioeconomic status. Lower SES pts are treated with more induction chemo and less novel therapies, likely contributing to worse survival. More at #ASH24 www.ajmc.com/view/real-wo...

Big day for our field! 🎉

Excited for #ASH2024! Come check out updates of our clinical trial with oral azacitidine and venetoclax in newly diagnosed AML. Great responses in this population!

Can’t miss! Registered :)